



Contact: Tricia J. Richardson
Senior Manager, Investor Relations
1 240-268-2031

NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010

Rockville, MD (January 25, 2010)–/PRNewswire-FirstCall/-Novavax, Inc. (NASDAQ:NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the upcoming Phacilitate Vaccine Forum Washington 2010. The Conference will take place January 25–27, 2010 at the Grand Hyatt, Washington, D.C. Mr. John Trizzino, Senior Vice President of International and Government Alliances will be participating in a Focus Session: *Fast Tracking the development of – and path to licensure for – a novel manufacturing platform by utilizing it in pandemic influenza efforts* on January 26, 2010 at 4:15pm.

Dr. Rahul Singhvi, President and CEO will be presenting a Case Study: *Small Company/Big Company interplay: How does it all connect around manufacturing, supply chain, and the need for dose sparing?* on January 27, 2010 at 12:55 pm.

About Vaccine Forum Washington 2010

The conference program features a highly stimulating mixture of business, regulatory, investment and public policy topics, with the speaker panel featuring high level representatives of vaccine developers themselves, as well as key government agencies, non-government agencies and analysts. For more information visit: www.phacilitate.co.uk

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

###